{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:16:57Z","timestamp":1787919417844,"version":"build-2784847793"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025276","name":"Novo Nordisk USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic inflammation is implicated in the pathogenesis of cardiovascular disease, including heart failure (HF). We examined the association between systemic inflammation, indicated by elevated high-sensitivity C-reactive protein (hsCRP), and adverse clinical outcomes in individuals with HF with preserved ejection fraction (HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study identified individuals with HFpEF from the Komodo Healthcare Map\u2122 database (01\/01\/2016 to 12\/31\/2023) using a validated algorithm. Systemic inflammation status was established by hsCRP testing: with systemic inflammation if \u22651 hsCRP value of 2-10 mg\/L and without systemic inflammation if all hsCRP values &amp;lt;2 mg\/L. The relationship between hsCRP and risk for HF events, including all-cause mortality, HF hospitalization and urgent HF visits was examined using Cox proportional hazards models with multivariable adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 11,015 individuals with HFpEF and a qualifying hsCRP measurement were identified (mean age 66.4 years; 44% with systemic inflammation). The incidence rate of the composite HF endpoint was 103.2 per 1,000 person-years for those with systemic inflammation versus 83.3 for those without. Systemic inflammation was associated with a 21% increased risk of the composite HF endpoint (HR 1.21, 95% CI 1.11-1.31). Systemic inflammation was associated with increased risk of HF hospitalization (HR 1.17, 95% CI 1.03-1.33) and urgent HF visits (HR 1.21, 95% CI 1.08-1.35) but not all-cause mortality (HR 1.14, 95% CI 0.98-1.32).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systemic inflammation was associated with increased risk of future adverse CV-related outcomes in individuals with HFpEF, highlighting unmet clinical needs for this population and the potential to optimize their care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1872310","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:30:31Z","timestamp":1787916631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic inflammation and the risk of adverse clinical outcomes in heart failure with preserved ejection fraction"],"prefix":"10.3389","volume":"13","author":[{"given":"Chi","family":"Nguyen","sequence":"first","affiliation":[{"name":"Novo Nordisk Inc.","place":["Plainsboro, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.","place":["Plainsboro, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanth","family":"Iyer","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.","place":["Plainsboro, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ackermann","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.","place":["Plainsboro, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Skaar","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.","place":["Plainsboro, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Chow","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.","place":["Plainsboro, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Ryali","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.","place":["Plainsboro, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Harrington","sequence":"additional","affiliation":[{"name":"University of Colorado Health","place":["Aurora, CO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America","volume":"31","author":"Bozkurt","year":"2024","journal-title":"J Card Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American heart association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11883-024-01259-7","article-title":"IL-6 and cardiovascular risk: a narrative review","volume":"27","author":"Mehta","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11897-019-00450-1","article-title":"Reappraisal of inflammatory biomarkers in heart failure","volume":"17","author":"Chaikijurajai","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/ejhf.1482","article-title":"The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study","volume":"21","author":"Markousis-Mavrogenis","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"131818","DOI":"10.1016\/j.ijcard.2024.131818","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: findings from TOPCAT","volume":"402","author":"Ferreira","year":"2024","journal-title":"Int J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e06","DOI":"10.15420\/usc.2024.25","article-title":"High-sensitivity C-reactive protein in atherosclerotic cardiovascular disease: to measure or not to measure?","volume":"19","author":"Mehta","year":"2025","journal-title":"US Cardiol"},{"key":"B12","year":""},{"key":"B13","doi-asserted-by":"publisher","first-page":"e004700","DOI":"10.1161\/CIRCOUTCOMES.118.004700","article-title":"Development and preliminary validation of a medicare claims-based model to predict left ventricular ejection fraction class in patients with heart failure","volume":"11","author":"Desai","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0252903","DOI":"10.1371\/journal.pone.0252903","article-title":"External validation of a claims-based model to predict left ventricular ejection fraction class in patients with heart failure","volume":"16","author":"Mahesri","year":"2021","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10741-020-09927-x","article-title":"Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"26","author":"Lakhani","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1461073","DOI":"10.3389\/fcvm.2024.1461073","article-title":"Association of systemic inflammatory markers with clinical adverse prognosis and outcomes in HFpEF: a systematic review and meta-analysis of cohort studies","volume":"11","author":"Fu","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1161\/CIR.0000000000000677","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100950","DOI":"10.1016\/j.ajpc.2025.100950","article-title":"Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS)","volume":"21","author":"Lv","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1125687","DOI":"10.3389\/fcvm.2023.1125687","article-title":"Inflammation as a therapeutic target in heart failure with preserved ejection fraction","volume":"10","author":"Peh","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10741-025-10491-5","article-title":"Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis","volume":"30","author":"Davison","year":"2025","journal-title":"Heart Fail Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e031251","DOI":"10.1161\/JAHA.123.031251","article-title":"Differential response to interleukin-1 blockade with anakinra on cardiorespiratory fitness in patients with heart failure with preserved ejection fraction stratified according to left ventricular ejection fraction","volume":"12","author":"Golino","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e013546","DOI":"10.1161\/CIRCHEARTFAILURE.125.013546","article-title":"Resolution of systemic inflammation in patients with recently decompensated heart failure with reduced ejection fraction with and without interleukin-1 blockade by anakinra","volume":"19","author":"Van Tassell","year":"2026","journal-title":"Circ Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100691","DOI":"10.1016\/j.jacadv.2023.100691","article-title":"BNP\/NT-proBNP levels are sensitive markers of impaired prognosis in patients without heart failure","volume":"2","author":"Volpe","year":"2023","journal-title":"JACC Adv"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1872310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:30:31Z","timestamp":1787916631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1872310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":30,"alternative-id":["10.3389\/fcvm.2026.1872310"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1872310","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1872310"}}